Floyd A. Beckford
Floyd A. Beckford publishes mostly in Oncology, Organic Chemistry and Molecular Biology, on topics such as Metal complexes synthesis and properties, Protein Interaction Studies and Fluorescence Analysis and Synthesis and Characterization of Heterocyclic Compounds.
- World rank
- #2,902,661 of 7,710,434 ranked researchers
- Rank in United States
- #837,739 of 1,627,098
- Works
- 45
- Citations
- 751
- Citations per work
- 16.7
What does Floyd A. Beckford research?
Floyd A. Beckford's work is mostly in Chemistry (31%), Medicine (26%), Biochemistry, Genetics and Molecular Biology (18%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Physical Sciences1942.3%
- Chemistry1430.8%
- Materials Science37.7%
- Computer Science23.8%
- Health Sciences1226.0%
- Medicine1226.0%
- Life Sciences818.3%
- Everything else613.4%
- 1Oncology26% of their works
- 2Organic Chemistry26% of their works
- 3Molecular Biology18% of their works
- 4Materials Chemistry8% of their works
- 5Inorganic Chemistry5% of their works
- 6Computational Theory and Mathematics4% of their works
Research topics
- Metal complexes synthesis and properties
- Protein Interaction Studies and Fluorescence Analysis
- Synthesis and Characterization of Heterocyclic Compounds
- Synthesis and biological activity
- Lanthanide and Transition Metal Complexes
- Protein Structure and Dynamics
- Computational Drug Discovery Methods
- Magnetism in coordination complexes
Which keywords describe Floyd A. Beckford's research?
The keywords of their largest research topics: Anticancer Agents, Cisplatin Resistance, Platinum-Based Drugs, Molecular Docking, Medicinal Chemistry, Protein Binding, Serum Albumin and Synthesis.
- Structure
- Protein
- Drug Target Identification
- MRI Contrast Agents
- Heterocyclic Compounds
- Synthesis
- Protein Binding
- Molecular Docking
- Cisplatin Resistance
- Anticancer Agents
- Platinum-Based Drugs
- Medicinal Chemistry
- Serum Albumin
- Triazines
- Lanthanide Luminescence
- Tubulin Inhibitors
- Lanthanide Complexes
- Single-Molecule Magnets
- Virtual Screening
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Anticancer Agents292 topics
- Cisplatin Resistance241 topic
- Platinum-Based Drugs241 topic
- Molecular Docking163 topics
- Medicinal Chemistry92 topics
- Protein Binding61 topic
- Serum Albumin61 topic
- Synthesis61 topic
- Triazines61 topic
- Heterocyclic Compounds51 topic
- Lanthanide Luminescence51 topic
- MRI Contrast Agents51 topic
- Tubulin Inhibitors51 topic
- Drug Target Identification41 topic
- Lanthanide Complexes41 topic
- Protein41 topic
- Single-Molecule Magnets41 topic
- Structure41 topic
- Virtual Screening41 topic
Where does Floyd A. Beckford work?
Floyd A. Beckford's main affiliation in the publication record is Lyon College, United States.
How many publications and citations does Floyd A. Beckford have?
OpenAlex counts 45 works and 751 citations for Floyd A. Beckford, an h-index of 14, ranking #2,902,661 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Floyd A. Beckford. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.